Clinical Competition Candidate
ZOLINZA
ZOLINZA carries substance and product and use-code patents, moderate complexity (2/5), and meaningful clinical competition (5/5). The listed expiry window is approximately 20 months away. Active clinical competition may compress the generic entry window.
LOE window
20months
to latest listed patent expiry (March 18, 2028)
Expiry attractiveness: 5/5
Patent profile
Substance patent (listed)
Product / formulation patent (listed)
Use-code patent (listed)
Patent count: 3
Complexity score: 2/5
Clinical competition
Score: 5/5
Active trials linked: 289
Phase 2/3 trials: 161
Higher scores indicate more trial activity for this ingredient — a proxy for competitive generic interest.
Drug overview
Active ingredient: VORINOSTAT
Applicant (NDA holder): MERCK SHARP AND DOHME LLC A SUB OF MERCK AND CO INC
Confidence: High